Search results

Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.

Result type

Technology appraisal guidance

Published

8 May 2025

Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.

Result type

Technology appraisal guidance

Published

3 August 2022

Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.

Result type

Technology appraisal guidance

Published

16 March 2022

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.

Result type

Technology appraisal guidance

Last updated

1 May 2024

Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go. It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking.

Result type

NICE guideline

Last updated

4 February 2025

Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

30 September 2020

Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

Result type

Technology appraisal guidance

Published

28 October 2021

Evidence-based recommendations on talazoparib (Talzenna) for HER2-negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults.

Result type

Technology appraisal guidance

Published

21 February 2024

Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.

Result type

Technology appraisal guidance

Published

25 November 2009

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.

Result type

Technology appraisal guidance

Published

1 February 2023

Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.

Result type

Technology appraisal guidance

Published

29 June 2022

Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy.

Result type

Technology appraisal guidance

Published

31 March 2021

This guideline covers the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.

Result type

Clinical guideline

Last updated

3 June 2025

This quality standard covers managing prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement.

Result type

Quality standard

Last updated

30 December 2021